Colorectal Cancer – Geographic Focus: China – China In-Depth – Colorectal Cancer
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in that country by 2033. Treatment of metastatic disease is dominated by chemotherapy regimens prescribed in combination with VEGF inhibitors and/or EGFR inhibitors. The recent launch of PD-L1 inhibitors—Merck’s Keytruda and Alphamab Oncology’s Enweida—and the anticipated launch and uptake of targeted therapies—Amgen’s Vectibix, Bayer’s Zaltrap, and Chia Tai Tianqing Pharmaceutical’s Focus V—during the 2023-2033 period will lead to significant growth of this market. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List (NRDL)—will influence the launch and uptake of new therapies during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this highly lucrative market.
- How large is China’s drug-treatable colorectal cancer population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts’ insights into current treatments?
- What are the key unmet needs in the management of colorectal cancer?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
Release date
October 2024
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists.
Epidemiology
Diagnosed incidence of colorectal cancer in urban versus rural China; clinically and commercially relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase 3 / preregistered: 10+ drugs.
